Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio’s antiviral portfolio SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.
